Brief: Pacira Biosciences Announces First Patient Dosed In Phase 2 Study Evaluating Safety And Efficacy Of Pcrx-201 For The Treatment Of Osteoarthritis Of The Knee
03/04/2025 13:06
April 3 (Reuters) - Pacira Biosciences Inc PCRX.O: PACIRA BIOSCIENCES ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 STUDY EVALUATING SAFETY AND EFFICACY OF PCRX-201 FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE PACIRA BIOSCIENCES INC - TOPLINE RESULTS EXPECTED LATE 2026 Source text: ID:nGNX5VPhJq Further company coverage: PCRX.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Pacira Biosciences
See all newsBrief: Pacira Biosciences Inc - Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "For" All Of Pacira's Director Nominees
Brief: Pacira Biosciences Urges Stockholders To Vote "For" Election Of Pacira's Nominees On Blue Proxy Card
Brief: Doma Perpetual Urges Pacira Biosciences Shareholders To Judge Sale Price Adequacy
Brief: Doma Perpetual Capital Management Calls For Removal Of Pacira CEO And Strategic Sale
Brief: Pacira Biosciences Sends Letter To Stockholders Reiterating Superior Qualifications Of Its Board Nominees